Plus Therapeutics Inc
PSTV0.732USD
+0.147+25.15%
Horário de mercado （ET）Cotações atrasadas em 15 min
12.45MValor de mercado
PerdaP/L TTM
Mais detalhes de Plus Therapeutics Inc Empresa
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Its radiotherapeutic candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC). The Company’s Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat many solid organ cancers.
Informações da empresa
Código da empresaPSTV
Nome da EmpresaPlus Therapeutics Inc
Data de listagemAug 09, 2000
CEODr. Marc H. Hedrick, M.D.
Número de funcionários21
Tipo de títulosOrdinary Share
Fim do ano fiscalAug 09
Endereço4200 Marathon Blvd.
CidadeAUSTIN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal78756
Telefone17372557194
Sitehttp://www.plustherapeutics.com/
Código da empresaPSTV
Data de listagemAug 09, 2000
CEODr. Marc H. Hedrick, M.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
29.33K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.43K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Michael Stanley Rosol, Ph.D.
Dr. Michael Stanley Rosol, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Richard J. (Rick) Hawkins
Mr. Richard J. (Rick) Hawkins
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Robert P. Lenk, Ph.D.
Dr. Robert P. Lenk, Ph.D.
Independent Director
Independent Director
29.33K
--
Mr. Howard Clowes, J.D.
Mr. Howard Clowes, J.D.
Independent Director
Independent Director
26.50K
--
Dr. Marc H. Hedrick, M.D.
Dr. Marc H. Hedrick, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
20.43K
--
Mr. Kyle Guse, Esq.
Mr. Kyle Guse, Esq.
Independent Director
Independent Director
--
--
Dr. Annigje (An) van Es-Johansson, M.D.
Dr. Annigje (An) van Es-Johansson, M.D.
Independent Director
Independent Director
--
--
Mr. Andrew Sims, CPA
Mr. Andrew Sims, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Moeda: USDAtualizado em: ter, 4 de mar
Moeda: USDAtualizado em: ter, 4 de mar
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
Por RegiãoUSD
Nome
Receita
Proporção
Japan
2.06M
77.05%
Americas
293.00K
10.97%
EMEA
270.00K
10.11%
Asia Pacific
50.00K
1.87%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Consumable
2.17M
81.21%
Other products
277.00K
10.37%
Device
225.00K
8.42%
Distribuição de ações
Atualizado em: sex, 27 de jun
Atualizado em: sex, 27 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Great Point Capital LLC
1.46%
S.H.N. Financial Investments Ltd
1.46%
HRT Financial LP
0.17%
Susquehanna International Group, LLP
0.13%
Geode Capital Management, L.L.C.
0.09%
Other
96.68%
Investidores
Investidores
Proporção
Great Point Capital LLC
1.46%
S.H.N. Financial Investments Ltd
1.46%
HRT Financial LP
0.17%
Susquehanna International Group, LLP
0.13%
Geode Capital Management, L.L.C.
0.09%
Other
96.68%
Tipos de investidores
Investidores
Proporção
Investment Advisor
1.91%
Corporation
1.46%
Individual Investor
0.24%
Investment Advisor/Hedge Fund
0.10%
Research Firm
0.07%
Hedge Fund
0.04%
Other
96.19%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
34
2.31M
3.81%
-2.38M
2025Q1
40
2.31M
11.85%
+1.40M
2024Q4
42
829.50K
14.07%
-98.90K
2024Q3
44
822.91K
13.96%
-122.82K
2024Q2
46
793.04K
13.90%
-131.21K
2024Q1
46
164.14K
3.77%
-119.25K
2023Q4
47
203.09K
4.50%
+1.47K
2023Q3
47
127.65K
2.90%
-110.39K
2023Q2
45
114.35K
4.03%
-124.09K
2023Q1
46
144.27K
6.00%
-86.09K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Great Point Capital LLC
885.45K
1.74%
--
--
Apr 18, 2025
S.H.N. Financial Investments Ltd
885.45K
1.74%
--
--
Apr 18, 2025
HRT Financial LP
102.06K
0.2%
+102.06K
--
Mar 31, 2025
Susquehanna International Group, LLP
80.50K
0.16%
+80.50K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
57.05K
0.11%
-1.10K
-1.89%
Mar 31, 2025
Petersen (Gregory B)
48.92K
0.1%
--
--
Mar 04, 2025
Virtu Americas LLC
40.03K
0.08%
+40.03K
--
Mar 31, 2025
UBS Financial Services, Inc.
33.44K
0.07%
+33.44K
--
Mar 31, 2025
The Vanguard Group, Inc.
32.54K
0.06%
--
--
Mar 31, 2025
Lenk (Robert P)
29.33K
0.06%
--
--
Apr 18, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Data
Tipo
Proporção
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
Apr 28, 2023
Merger
15<1
